Salud

Ciencia estudia cómo ganarle juego a variantes de coronavirus que podrían restar eficacia a vacunas

Indicios sobre posible reducción para prevenir la enfermedad hacen que científicos en todo el mundo se vuelquen a analizar cómo lograr mejorar el impacto, aseguran que ‘no todo está perdido’

(FILES) In this file photo taken on December 15, 2020, Rocky Mountain Regional VA Medical Center investigational pharmacy technician Sara Berech prepares a dose of the Johnson & Johnson COVID-19 vaccine for a clinical trial in Aurora, Colorado. - Johnson & Johnson's single-shot Covid-19 vaccine has an overall efficacy of 66 percent, the company announced on January 29, 2021, following results from a phase 3 trial of almost 44,000 people across many countries. The figure however was as high as 72 percent in the United States but went down to 57 percent in South Africa, where a more transmissible variant is dominant. (Photo by Michael Ciaglo / GETTY IMAGES NORTH AMERICA / AFP) / RESTRICTED TO EDITORIAL USE
(FILES) In this file photo taken on December 15, 2020, Rocky Mountain Regional VA Medical Center investigational pharmacy technician Sara Berech prepares a dose of the Johnson & Johnson COVID-19 vaccine for a clinical trial in Aurora, Colorado. - Johnson & Johnson's single-shot Covid-19 vaccine has an overall efficacy of 66 percent, the company announced on January 29, 2021, following results from a phase 3 trial of almost 44,000 people across many countries. The figure however was as high as 72 percent in the United States but went down to 57 percent in South Africa, where a more transmissible variant is dominant. (Photo by Michael Ciaglo / GETTY IMAGES NORTH AMERICA / AFP) / RESTRICTED TO EDITORIAL USE MICHAEL CIAGLO
Laboratorios farmacéuticos e institutos de investigación en universidades y centros independientes buscan tener respuestas para responder ante las nuevas variantes de covid-19 que eventualmente podrían restarle eficacia a vacunas. Fotografía: Michael Ciaglo / Getty Images North America (MICHAEL CIAGLO/AFP)

“Sí hay consenso general de que algunas variantes del SARS-CoV-2 (virus causante de la covid-19) están reduciendo la eficacia de las vacunas, por eso debemos trabajar”.

Linda-Gail Bekker, médico especialista en Inmunología, habló de su preocupación de cómo algunas variantes del virus podrían burlar las vacunas existentes, no al punto de que estas no funcionen, pero sí de que su eficacia no sea la esperada.

‌
‌

‌

‌
‌

‌

‌